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Abstract
Objectives To develop guidelines describing a standardised
approach to patient preparation and acquisition protocols for
magnetic resonance imaging (MRI), computed tomography
(CT) and ultrasound (US) of the small bowel and colon, with
an emphasis on imaging inflammatory bowel disease.
Methods An expert consensus committee of 13 members
from the European Society of Gastrointestinal and
Abdominal Radiology (ESGAR) and European Society of
Paediatric Radiology (ESPR) undertook a six-stage modified
Delphi process, including a detailed literature review, to create
a series of consensus statements concerning patient prepara-
tion, imaging hardware and image acquisition protocols.
Results One hundred and fifty-seven statements were scored
for agreement by the panel of which 129 statements (82 %)
achieved immediate consensus with a further 19 (12 %)
achieving consensus after appropriate modification. Nine
(6 %) statements were rejected as consensus could not be
reached.
Conclusions These expert consensus recommendations can
be used to help guide cross-sectional radiological practice
for imaging the small bowel and colon.
Key points
• Cross-sectional imaging is increasingly used to evaluate the
bowel
• Image quality is paramount to achieving high diagnostic
accuracy
•Guidelines concerning patient preparation and image acqui-
sition protocols are provided
Keywords Crohn disease . Small bowel . Computed
tomography .Magnetic resonance imaging . Ultrasound
Introduction
Increased utilisation of cross-sectional techniques to image the
bowel has occurred in recent years, particularly in the context
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of inflammatory bowel disease. A large body of evidence now
supports the use of computed tomography (CT), magnetic
resonance imaging (MRI) and ultrasound (US) in this context,
and recent expert guidelines recommend cross-sectional im-
aging as first line in the diagnosis, staging and follow up of
inflammatory bowel disease [1]. In commonwith many radio-
logical tests, image quality is paramount to achieving high
diagnostic accuracy, and there is a risk that rapid dissemina-
tion can occur without sufficient attention to acquisition pro-
tocols. This is particularly pertinent when imaging the bowel,
a complex, motile organ where non-diagnostic examinations
are a particular risk. For example, adequate bowel distension
is important prior to enteric imaging and correct sequence
selection is central to high quality MRI [1]. The European
Society of Gastrointestinal and Abdominal Radiology
(ESGAR) has formed an expert consensus committee to con-
struct detailed guidelines for performing MRI, CT and US
when investigating disorders of the small bowel and colon,
with an emphasis on inflammatory bowel disease.
Representatives from the European Society of Paediatric
Radiology (ESPR) also participated, given the widespread
use of cross-sectional imaging in the paediatric age group.
The specific remit of the committee was to produce up to date
guidelines concerning patient preparation and image acquisi-
tion protocols for MR enterography (MRE)/CT enterography
(CTE), MR enteroclysis/CT enteroclysis and US/
hydrosonography (hydroUS). Standards for interpretation
and reporting examinations, together with consideration of
clinical indications, diagnostic accuracy and advantages and
disadvantages of each modality were beyond the remit of the
committee and covered by the recent joint European Crohn’s
and Colitis Organisation (ECCO)/ESGAR recommendations
for imaging in inflammatory bowel disease [1]. This article
reports the recommendations of the expert panel.
Methods
Expert panel selection
A call for expressions of interest to take part in the pro-
cess was circulated to all ESGAR members. From those
expressing interest, a panel of ten members (including the
chair) were invited based on publication record in the
field and geographical location to ensure, as far as possi-
ble, appropriate representation across the ESGAR mem-
bership. The committee was then supplemented by three
members chosen by the ESPR for all paediatric consider-
ations, to give a total of 13 individuals. Two research
fellows were added to help with the literature review
and document construction, but they did not take part in
committee consensus voting.
Consensus process
A modified Delphi approach based on the RAND-UCLA ap-
propriateness method was utilised [2], encompassing a de-
tailed literature review and collective judgement of experts,
including electronic and face to face discussion [3]. A sum-
mary of the process is given in Fig. 1
STEP 1 
Questionnaire construction to include all content 
relevant to the guidelines. Working groups (WG) set up 
STEP 2 
Questionnaire completed by all committee members 
STEP 3 
Literature search
STEP 4 
Draft consensus statements produced by each WG 
based on literature review and questionnaire responses  
STEP 5 
Committee members indicate agreement or otherwise 
for each individual draft consensus statement (1-5)  
STEP 6 
Acceptance of agreed statements (>80% members 
score 4 or 5) 
Face to face meeting to modify statements without 
agreement 
Committee members indicate agreement or otherwise 
for each modified consensus statement (1-5) 
Final consensus statements 
Fig. 1 Summary of consensus process
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Step 1—Questionnaire construction
The consensus committee met for a face to face discus-
sion to define the scope and aims of the process (11
June 2015), and an initial questionnaire including 185
items was drafted by the chair and then circulated elec-
tronically to all committee members. Each item consisted
of a specific question with an appropriate range of pos-
sible responses, including an option for free text. The
questionnaire was split into four broad topics: (1) patient
prepara t ion for MRE/MR enteroc lys is /CTE/CT
enteroclysis, (2) MRE/ MR enteroclysis technique and
sequence selection, (3) CTE/CT enteroclysis technique,
and (4) enteric US patient preparation and technique.
Items were duplicated for both adult and paediatric pop-
ulations as appropriate. The questionnaire was then mod-
ified based on feedback from committee members and a
final version agreed upon, which defined individual
topics requiring consensus statements. The consensus
committee was split into four subgroups matching the
four broad topics. Members of ESPR formed a fifth sub-
group for paediatric considerations throughout the
questionnaire.
Step 2—Questionnaire completion
The agreed questionnaire was circulated electronically to
committee members who completed their responses to each
item in order to document initial expert opinion. The re-
sponses were summarised centrally.
Step 3—Literature search
A radiology research fellow performed a detailed literature
search based on the strategy used by Puylaert et al. [4]. Full
details of the search are given in Table 1. The fellow reviewed
the retrieved abstracts and selected those pertinent to the items
in the questionnaire. Queries were resolved by face to face
discussion with the committee chair. The final search retrieved
a list of 727 publications, which were circulated to all com-
mittee members, along with full abstracts. Working groups
were at liberty to update the literature search at their
discretion.
Step 4—Draft consensus statements
Within their working groups, committee members drafted
consensus statements for each item listed in the questionnaire
based on the available literature and expert opinion as appro-
priate (using the summarised committee responses to the ques-
tionnaire). Members were instructed to always base their state-
ments on the retrieved literature wherever possible, and to this
end graded the strength of retrieved relevant publications from
I (high) to V (low) using the criteria of the Oxford Centre for
Evidence Based Medicine [5] during their review process. If
no relevant literature was available for a particular item, mem-
bers used expert opinion to construct the consensus state-
ments. Each working group produced a list of draft consensus
statements, a summary of the supporting literature and table of
relevant publications with evidence strength grade, which was
then circulated to the whole committee.
Step 5—Committee voting
All committee members graded their agreement with each
draft consensus statement from 1 to 5 according to the follow-
ing definitions; 1, strongly disagree; 2, somewhat disagree; 3,
undecided; 4, somewhat agree; 5, strongly agree. The re-
sponses were summarised centrally.
Table 1 Literature search strategy (from Puylaert et al. [4])
Search
details
Time period: January 1983–December 2015
Medline search
1 Crohn’s disease
2 Crohn [tiab]
3 Inflammatory bowel disease
4 1 OR 2 OR 3
5 Computed tomography
6 CT [tiab]
7 MRI
8 “Magnetic resonance” [All fields] OR (“magnetic” [All
fields] AND “resonance” [All fields])
9 Ultrasound
10 5 OR 6 OR 7 OR 8 OR 9
11 4 AND 10
Embase search
1 Crohn’s disease.ab,ti,sh,kw
2 Inflammatory bowel disease.ab,ti,sh,kw
3 1 OR 2
4 Computer Assisted Tomography.ab,ti,sh,kw
5 Exp Computer Assisted Tomography/
6 Nuclear magnetic resonance imaging.ab,ti,sh,kw
7 Exp Nuclear magnetic resonance imaging/
8 Echography.ab,ti,sh,kw
9 Exp echography/
10 4 OR 5 OR 6 OR 7 OR 8 OR 9
11 3 AND 10
Cochrane search
1 Crohn disease [Mesh]
2 Inflammatory bowel disease [Mesh]
3 1 OR 2
4 Diagnostic techniques and procedures [Mesh]
5 3 AND 4
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Step 6—Construction of final consensus statements
Those statements achieving a score of 4 or 5 by at least
80 % of committee members in step 5 were accepted into
the final set of consensus statements. Those not achiev-
ing this were re-discussed at a face to face meeting of
the committee (6 March 2016) attended by seven mem-
bers. Those members who were unable to attend contrib-
uted via electronic submissions, which were presented by
the chair. Statements not achieving consensus were
reviewed with reference to the literature summaries pro-
duced by each working group, and committee member
opinions were sought. The statement was then either
modified or deleted if it was clear consensus could not
be reached. The list of revised statements was
recirculated to the whole committee who graded agree-
ment from 1 to 5 as in step 5. Those statements achiev-
ing a score of 4 or 5 by at least 80 % of committee
members were added to the final set of consensus
statements.
Results
The current clinical practice of the panel members is
summarised in Table 2. The 13 voting committee members
were from the UK (2), Sweden (1), France (4), Netherlands
(1), Korea (1), Italy (2), Spain (1) and Ireland (1). Eleven out
of 13 panels members used 1.5 T for MR and 2 members used
3 T routinely. Nine panel members had access to CT with at
least 64 slices and two had access to a 16-slice scanner.
The final agreed upon questionnaire consisted of 157 items
generating individual consensus statements. At the first round
of committee voting, 129 statements achieved consensus ac-
cording to the a priori definition. The remaining 28 statements
did not achieve consensus and were modified to produce a set
of 19 statements, all of which achieved consensus agreement
in the second round of voting. Those statements which could
not be modified to reach consensus were deleted and are
shown in Table 3. The final set of 148 consensus statements
underwent further editing by the committee chair to avoid
duplication, leaving a total of 125 final consensus statements
shown in Table 4.
Discussion
The committee considered four main topics as the basis for the
consensus statements, with an additional section for specific
paediatric considerations.
General patient preparation and basic MRI and CT
technique
There is little evidence on optimal patient preparation prior to
MRI or CT, and recommendations with regard to periods of
nil by mouth for solids and fluids were based mainly on expert
opinion. Ingestion of sparkling water is not recommend-
ed due to the risk of producing intraluminal gas arte-
facts, particularly during MRI. There is good evidence
that the accuracy of MRI is improved by administration
of oral contrast, in comparison to unprepared MRI [6].
Many oral contrast agents are described in the literature
[7–13], but no strong evidence from patient cohorts sup-
ports one particular oral contrast agent over another. A
number of agents are therefore recommended, usually
with hyperosmolar properties [14] and ingested over
46-60 min prior to the examination [15]. Evidence
pertaining to the optimal volume of oral contrast agent
is limited, although a study in ten healthy volunteers
showed inferior distension quality when the ingested
volume of oral contrast agent is below 1,000 ml [12].
There was no consensus as to whether the oral contrast
agent should be split into two aliquots prior to ingestion
or drunk continuously, and both approaches seem ac-
ceptable. Although there is evidence that examinations
of reasonable quality can be achieved with as little as
450 ml of oral contrast agent [16], no consensus was
reached on the minimum oral contrast load for accept-
able MRE or CTE and in clinical practice this is usually
judged on a case by case basis. Plugging of a stoma is
recommended to improve enteric distension, but there is no
direct scientific evidence to support this approach. Similarly,
in patients with significant bowel resection, scanning earlier,
for example at 30 min, may be advisable.
The recommended choice of enteric contrast agents for
enteroclysis examinations in general mirrors those recom-
mended for enterography. However, the use of water during
CT enteroclysis was included given the speed of CT acquisi-
tion, minimising the detrimental effects of gut absorption seen
with longer examination times. The optimal volume of
Table 2 Current clinical practice of expert committee members
(n = 13)
Panel members
performing routinely
Mean annual
case load
MRE 13 313
MR enteroclysis 4 14
CTE 8 70
CT enteroclysis 4 23
US 5 110
MRE MR enterography, CTE CT enterography, US enteric ultrasound
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contrast agent for both CT enteroclysis and MR enteroclysis
should be based on real time on table monitoring.
The routine use of bowel laxatives and rectal enema is not
recommended, although there is good evidence that detection
of colonic inflammation with MRI is improved with adminis-
tration of a water enema in comparison to evaluating the un-
prepared colon [17, 18]. If dedicated colonic evaluation with
MRI is required, it is therefore recommended to prepare the
colon using a water enema [19, 20], or with prolonged oral
preparation [21].
The use of an automated pump for oral contrast adminis-
tration during enteroclysis is recommended, although hand
injection is an acceptable alternative.
Although there is some data suggesting superior bow-
el distension is achieved in the prone position [22],
there is no strong evidence this improves diagnostic
accuracy. While also recognising that some patients
have difficulty lying prone, either supine or prone position-
ing is considered acceptable.
MRE/MR enteroclysis technical considerations
and sequences selection
The use of phased array coils at either 1.5 T or 3 T is recom-
mended. There was no consensus for which field strength was
optimal for enteric MRI, with data suggesting high image
quality is routinely possible on 3 T as well as good quality
1.5 T [23, 24].
There is some evidence that MRE can achieve high
diagnostic accuracy without use of a spasmolytic [25],
although other data shows significantly superior disten-
sion and with the use of these agents [26], particularly
in the proximal small bowel, as well as a beneficial
effect on study quality by removing peristalsis. Use of
spasmolytic prior to MRE and MR enteroclysis is there-
fore recommended. The literature suggests both hyo-
scine butyl bromide and glucagon are acceptable agents
with differing properties in terms on speed of onset and
duration of effect, although both are most effective
when given intravenously [27]. Whilst there is volunteer
data suggesting superiority of glucagon in achieving
complete aperistalsis [28], there is currently no evidence
this translates into improved diagnostic accuracy and
based on cost, availability and expert opinion, hyoscine
butylbromide is recommended as the firs t - l ine
spasmlotyic, with glucagon as second line.
There was no consensus as to the optimal timing of spas-
molytic administration or whether the dose should be split in
an attempt to maintain aperistalsis throughout the duration of
the MR examination. It is therefore recommended that spas-
molytics should be administered before motion sensitive se-
quences (typically fast spin echo T2-weighted sequence and
post contrast T1-weighted images) and either a single or a split
dose are acceptable.
There is no available evidence informing the optimal com-
bination of T2-weighted and steady state free precession gra-
dient echo (SSFP GE) sequences, although nearly all studies
in the literature utilise both sequence types. Recommendations
were therefore mainly based on expert opinion. The use of
post-gadolinium T1-weighted images are recommended with
data suggesting increased diagnostic accuracy with their use
[29, 30], and utility of bowel wall enhancement in validated
disease activity scores [31, 32] . There was no available evi-
dence suggesting a single optimal time for post-gadolinium
image acquisition, and the recommended options are based on
mainly expert opinion.
There is increasing evidence in support of quantified small
bowel motility to improve diagnostic accuracy [33, 34], assess
disease activity [35–38] and evaluate treatment response [39].
However, at the current time the panel recommends that cine
motility sequences remain optional. Similarly, the use of
diffusion-weighted imaging (DWI) is increasing, with data
supporting its role for disease identification and activity as-
sessment [40–45], and a potential replacement for i.v.
Table 3 Statements for which consensus could not be reached after attempted modification
Statement
• It is recommended that the minimal volume of oral contrast for dedicated MRE/MR enteroclysis or CTE/CT enteroclysis is 500 ml (IV)
• Splitting the oral contrast into two loads and scanning after ingestion of each to improve small bowel distension is not recommended (V)
• The optimal field strength for MRE/MR enteroclysis is 1.5 T (IV)
• It is recommended to split-the dose of spasmolytics before T2W sequences and before contrast-enhanced T1W sequences (V)
• It is recommended to routinely use small bowel motility sequences during MRE (V)
• It is recommended to routinely use an axial diffusion-weighted sequence during MRE/MR enteroclysis (V)
• It is recommended that if a spasmolytic is used, and hyoscine butylbromide is unavailable/ contraindicated, a second-line agent is employed during
CTE/CT enteroclysis
• It is recommended to administer a spasmolytic before MRE in the paediatric population (V)
• It is recommended that if CTscanning is used in the paediatric population, no specific preparation is usually required although administration of positive
oral contrast could be considered; for example, prior to percutaneous drainage of abscesses (V)
Evidence strength (Oxford Centre for Evidence Based Medicine) shown in parentheses
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Table 4 Final list of consensus statements (achieving agreement score 4 or 5 by at least 80 % of committee members) a
ADULT PATIENTS
1. Patient preparation and basic technique—MRE/MR enteroclysis/CTE/CT enteroclysis
Patient preparation—general
• It is recommended that routine medications should not be stopped (V)
• It is recommended that patients should not eat any solid food for 4-6 h (V)
• It is recommended that patients should not drink any fluid for 4-6 h, although non-sparkling water is permissible (V)
Basic technique—MRE and CTE
• There is no single preferred contrast agent for MRE or CTE. Recommended agents include mannitol (with or without locust bean gum), PEG, sorbitol and
lactulose amongst others (III)
• The optimal volume of oral contrast is 1,000-1,500 ml (III)
• It is recommended that ingestion time of oral contrast without previous major small bowel resection should be 46-60 min (V)
• It is recommended that when scanning patients with a stoma, the stoma should be plugged before oral contrast ingestion (V)
• It is not recommended that laxative bowel preparation is administered (V)
• It is not recommended that a rectal water enema is administered before a routine examination (V)
• It is recommended to administer a liquid enema or prolonged oral contrast preparation without laxative for dedicated colonic evaluation during CTE orMRE
(III)
• It is recommended to use water as the distension agent if a liquid rectal enema is used for dedicated colonic evaluation (V)
• It is recommended that the volume of a water rectal enema is based on patient tolerance if used for dedicated colonic evaluation (V)
Basic technique—MR enteroclysis and CT enteroclysis
• There is no single preferred contrast agent forMR enteroclysis. Recommended agents includemannitol (with or without locust bean gum), PEG, sorbitol and
lactulose amongst others (III)
• There is no single preferred contrast agent for CT enteroclysis. Recommended agents include mannitol (with or without locust bean gum), PEG, sorbitol,
lactulose and water amongst others (III)
• Fluoroscopic guidance for NJ tube insertion prior to MR enteroclysis/ CT enteroclysis is mandatory (V)
• It is recommended that the NJ tube for MR enteroclysis and CT enteroclysis should be 8-10 F(V)
• It is recommended that contrast infusion before MR enteroclysis or CT enteroclysis should be via an automated pump (V)
• It is recommended that the rate of contrast infusion before MR enteroclysis or CT enteroclysis should be between 80 and 120 ml/min (V)
• MRI fluoroscopic monitoring of small bowel filling during MR enteroclysis is mandatory (V)
• It is recommended that enteric contrast progression should be monitored on the MRI table during MR enteroclysis (V)
• It is recommended that enteric contrast progression should be monitored on the CT table during CT enteroclysis (V)
• The optimal volume of enteric contrast for MR enteroclysis or CT enteroclysis should be based on monitoring using MRI/CT (V)
Positioning
• It is recommended that patients can be scanned prone or supine during MRE, CTE, MR enteroclysis or CT enteroclysis (III)
2. MRE/MR enteroclysis—technical considerations and sequences selection
Hardware
• Both 1.5 and 3 T are adequate field strengths (II)
• The use of phased-array coils is mandatory (V)
Spasmolytic agents
• It is recommended that spasmolytic agents are administered during MRE and MR enteroclysis (II)
• The timing of spasmolytic agent administration should take into account the susceptibility of the applied MRI sequences to motion artefact (V)
• The recommended first line spasmolytic agent is i.v. hyoscine butylbromide (V)
• The recommended dose of i.v. hyoscine butylbromide is 20 mg (III)
• It is recommended to use a second line spasmolytic agent if the first line agent cannot be given (V)
• The recommended second line agent is i.v. glucagon (V)
• The recommended dose of i.v. glucagon is 1 mg (V)
Recommended sequences
• It is recommend to use the following sequences (V)
a) Axial and coronal fast spin echo (FSE) T2W sequences without fat saturation
b) Axial and coronal steady state free precession gradient echo (SSFP GE) sequences without fat saturation
c) An axial or coronal FSE T2W sequence with fat saturation
d) Non-enhanced coronal T1W sequence with fat saturation followed by contrast-enhanced coronal and axial T1W sequences with fat saturation
e) In patients with known or suspected inflammatory bowel disease, contrast-enhanced sequences should be in the enteric (45 s) or portal venous phase
(70 s)
f) In patients with suspected chronic GI bleeding contrast-enhanced sequences is should be in the arterial (30 s), enteric (45 s) or portal venous phase (70 s)
phase
• It is recommended that i.v. gadolinium is pump-injected with an infusion rate of 2 ml/s and a dosage of 0.1–0.2 mmol/kg (V)
• It is recommended that the maximal slice thickness for FSE T2W and SSFP GE sequences should be 5 mm (V)
• It is recommend that FSE T2W sequences may be performed in either 2D or 3D, although 2D is preferred. (V)
• It is recommended that the maximal slice thickness for axial and coronal T1W sequences, should be 3 mm (V)
• It is recommended that T1W sequences should be performed in 3D (V)
Optional sequences
• Optional additional sequences include an additional FSE T2W sequence with fat saturation, axial and coronal SSFP GE sequences with fat saturation, cine
motility and diffusion weighted imaging (V)
• It is recommended that a free breathing technique is used if diffusion-weighted sequences are performed (IV)
• It is recommended that diffusion-weighted sequences should include lower b values ranging from 0 or 50 and upper b values ranging from 600 to 900 (IV)
• It is recommended that the maximal slice thickness for a diffusion-weighted sequence should be 5 mm (V)
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Table 4 (continued)
• Coronal diffusion-weighted sequences are not recommended (V)
• Dynamic contrast-enhanced sequences are not mandatory, but may provide additional information in the form of quantitative measurements of
contrast enhancement (V)
• Magnetization transfer sequences are not recommended (V)
Scan coverage and duration
• It is recommended that scan coverage should include at least the small bowel and colon extended to include the perineum (V)
• It is recommended that in general the total acquisition time for should be equal to or less than 30min (V)
3. CTE/CTenteroclysis—technical considerations
Hardware
• MDCTwith at least 64 slices is optimal (V)
• MDCTwith 16 slices or more is considered adequate (V)
Spasmolytic agents
• The use of a spasmolytic agent during CTE/CT enteroclysis is optional (V)
• It is recommended that if a spasmolytic is used the first line agent is i.v. hyoscine butylbromide (V)
• The recommended dose of i.v. hyoscine butylbromide is 20mg (IV)
• The recommended second line agent is i.v. glucagon (V)
Scan acquisition—general
• It is recommended that a variable tube current is used, according to the tube voltage used and patient body habitus, but should be kept as low as
possible (V)
• It is recommended to use automatic exposure control (III)
• It is recommended that scan coverage should include the whole abdomen and pelvis including the liver (V)
• It is recommended that image-based or raw data-based iterative reconstruction is used if available (III)
• The use of multiplanar reformats is mandatory (III)
• It is recommended that the maximal slice thickness for displaying axial, coronal and sagittal reconstructed images should be 3mm (V)
• It is recommended that CT acquisition should be cranio-caudal (V)
• It is recommended that an upper dose exposure limit is defined (V)
• It is recommended that the cumulative value of radiation dose should be recorded, especially in patients affected by chronic conditions resulting in
repeat CT imaging (V)
Scan acquisition—known or suspected inflammatory bowel disease
• It is recommended that either an enteric phase or portal venous phase acquisition is performed (III)
• Additional acquisitions including pre-contrast, arterial, and delayed phase (6-7min) are not recommended (V)
• It is recommended that i.v. iodinated contrast should be pump injected at rate of 3-5ml/s (V)
• It is recommended that i.v. iodinated contrast iodine content is within a range of 300-370mg/ml (V)
• It is recommended that the i.v. iodinated contrast iodine dose should be varied according to the patients’ weight at 1.5ml/kg (V)
• It is recommended that the tube voltage should be within a range of 80-120 according to the patient body habitus (V)
Scan acquisition—suspected underlying GI bleeding
• Arterial and portal phases acquisitions are mandatory (V)
• It is recommended that i.v. iodinated contrast should be pump injected at rate of 3-5 ml/s (V)
• It is recommended that the i.v. iodinated contrast iodine dose should be varied according to the patients’ weight (V)
• It is recommended that the tube voltage should be within a range of 80-140 according to the patient body habitus (V)
4. Patient preparation and basic technique—enteric US
Patient preparation
• It is recommended that patients should be nil by mouth for solids for 4-6h (V)
• It is recommended patients should not drink any fluid for 4-6h prior to the procedure, although water is permissible. If examination of the extra
enteric organs is performed, patients should be nil by mouth as per standard protocols (V)
Hardware
• It is recommended that evaluation with both low and high frequency probes is performed (III)
• The optimal probe frequency for high resolution bowel imaging is 8-10MHz (V)
Basic technique—enteric US
• It is not recommended that laxative bowel preparation is administered (V)
• It is not recommended that a rectal water enema is administered before a routine examination (V)
• Use of an spasmolytic agent is not recommended (V)
• It is recommended that for dedicated colonic evaluation, a standard protocol without specific modification is used (V)
Basic technique—hydrosonography
• It is not recommended that laxative bowel preparation is administered (V)
• The use of a spasmolytic agent is not recommended (V)
• There is no single preferred contrast agent for hydosonography. Recommended agents include mannitol (with or without locust bean gum), PEG,
sorbitol and lactulose amongst others (V)
• It is recommended that the optimal volume of oral contrast for should exceed 500ml (V)
• It is recommended that ingestion time of oral contrast should be 45min (V)
Doppler and IV contrast—US and hydrosonography
• It is recommended to routinely use colour Doppler (II)
• The optimal Doppler flow setting is between 1 and 8cm/s (V)
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contrast-enhanced sequences [46]. It’s advantage over and
above conventional MRI sequences, however, is not yet fully
established [47] and it is also considered optional at present. It
is acknowledged that DWI may have particular utility in the
paediatric population [48], and recommendations regarding
image acquisition are given. Magnetisation transfer sequences
are promising [49] but with little supportive clinical data they
are not currently recommended.
CTE/CT enteroclysis technical considerations
There is little evidence for the optimal CT platform for
performing CTE and CT enteroclysis, but based on expert
opinion it is recommended that 16-slice CT is a minimum
and 64+ slices is optimal. The use of spasmolytic is optional
given the speed of CT image acquisition compared with MRI,
and the lack of data demonstrating a benefit of spasmolytic.
Table 4 (continued)
• Routine use of i.v. US contrast agent is not recommended (V)
• If i.v. contrast agent is given, the optimal dose of sulphur hexafluoride is 2.4-4.8ml (III)
• If i.v. contrast agent is given, the standard number of boluses of sulphur hexafluoride is 1 (V)
• If i.v. contrast agent is given, the maximum dose of sulphur hexafluoride is 4.8ml (V)
• Scanning between 10 and 40s after administration of sulphur hexafluoride i.v. contrast is mandatory (IV)
• Perfusion or time-intensity curves (e.g. ratio max enhancement/baseline) are not recommended (V)
• It is recommended that peak enhancement after contrast injection is measured (V)
Scan coverage
• It is recommended that formal reporting of enteric US should state whether the extra enteric organs were examined or not (V)
PAEDIATRIC PATIENTS—SPECIFIC CONSIDERATIONS
1. Patient preparation and basic technique—MRE/MR enteroclysis
Patient preparation
• It is recommended that children aged 6-9 should not eat any solid food for 2-4h (V)
• It is recommended that children aged 6-9 should not undergo fluid restriction (V)
• It is recommended that children aged over 9years should not eat any solid food for 4-6h (V)
• It is recommended that children aged over 9years should not undergo fluid restriction (V)
Basic technique—MRE
• It is recommended that the optimal volume of oral contrast for MRE or CTE is 20ml/kg with a maximum up to 25ml/kg (V)
• It is recommended that the use of a spasmolytic agent is optional (V)
• The recommended first line spasmolytic agent is i.v. hyoscine butylbromide, if a spasmolytic is used (V)
• The recommended dose of hyoscine butylbromide is 0.5mg/kg i.v. (V)
• The recommended second line agent is i.v. glucagon, if a spasmolytic agent is used (V)
•The recommended dose of glucagon in the paediatric population is 0.5mg (<24.9kg) and 1mg (>24.9kg), given as a slow infusion with i.v. saline at
an infusion rate at 1ml/s (V)
• The recommended dose of i.v. gadolinium is 0.1mmol/kg (V)
• It is recommended that the total scan duration should equal to or be less than 45min (V)
2. Patient preparation and basic technique—CTE/CT enteroclysis
• Use of CT scanning in children should be limited to exceptional circumstances, when US and/or MRE cannot address the clinical question (V)
• It is recommended that if CT scanning is used, only a portal phase from the diaphragm to the pubic symphysis is acquired (V)
3. Patient preparation and basic technique—enteric US
Patient preparation
• It is recommended that children aged 1-9 should not eat any solid food for 2-4h (V)
• It is recommended that children aged 1-9 years should be nil by mouth for carbonated and milk beverages for 2-4h. Ingestion of still water or non-
carbonated fruit juice is recommended (V)
• It is recommended that children aged over 9years should not eat any solid food for 4-6h (V)
• It is recommended that children aged over 9years should be nil by mouth for carbonated and milk beverages for 4-6h. Ingestion of still water or
non-carbonated fruit juice is recommended (V)
Basic technique—enteric US
• Use of laxative bowel preparation is not recommended (V)
• Additional colonic distension with a rectal water enema is not recommended (V)
• It is recommended that for dedicated colonic evaluation, a standard protocol without specific modification is used (V)
• Use of a spasmolytic agent is not recommended (V)
Doppler and IV contrast
• The use of i.v. US contrast is not recommended (V)
Scan coverage
• It is recommended that scan coverage should include an abdominal and pelvic examination, including the liver (V)
Evidence strength (Oxford Centre for Evidence Based Medicine) shown in parentheses
MRE MR enterography, CTE CT enterography, T1W T1-weighted, T2W T2-weighted
a 4 = somewhat agree, 5 = strongly agree
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As for MRI, hyoscine butylbromide is the recommended first
line agent if a spasmolytic is used. There was no consensus as
to the need for a second-line agent if hyoscine butylbromide
cannot be administered, but glucagon may used.
CT scan acquisition in either the enteric phase [50, 51] or
portal venous phase [52] is recommended in patients with
known or suspected inflammatory bowel disease, with no
clear evidence supporting one over the other [53]. For patients
with suspected GI bleeding, addition of an arterial phase ac-
quisition is considered mandatory to improve detection of
vascular lesions [54, 55].
Recurrent exposure of young patients to ionising ra-
diation from CT is a significant concern. Numerous
studies have documented high radiation exposure in
the IBD patient population, principally from CT
[56–61]. There are clear recommendations to minimise
patient dose by optimisation of tube voltage [62] and
tube current, together with routine use of iterative re-
construction techniques [50, 52, 63–68] which are in-
creasingly available and capable of producing high im-
age quality. For example, a tube voltage in the range of
80-100 kV can reduce radiation dose and increase con-
trast resolution [64]. The use of automated tube current
modulation is also recommended with good data show-
ing dose reduction with maintained image quality [69,
70]. It is recommended that cumulative radiation dose
should be recorded for patients with chronic conditions
requiring multiple radiological examinations. CT is not
recommended in paediatric practice unless there are no
alternatives.
Patient preparation and basic technique—enteric US
There is little evidence on optimal patient preparation prior to
US, and recommendations with regard to the period of nil by
mouth for food and liquids were based on mainly on expert
opinion. There is no evidence supporting the use of bowel
laxatives before US or hydroUS and use is not recommend.
Detailed assessment of the colon does not require additional
preparation.
Similar to MRE and CTE, a range of oral contrast agents
for hydosonography is described in the literature [71–73],
with no clear evidence for superiority of one over another. A
number of agents are therefore recommend, usually with
hyperosmolar properties. There is no specific evidence regard-
ing the optimal volume and ingestion protocol for oral contrast
and recommendations are based on expert opinion and mainly
mirror those of MRE and CTE.
There is no evidence of benefit from spasmolytic admin-
istration prior to enteric US, and diminishing the ability of
the practitioner to evaluate real time peristaltic activity in
the bowel detracts from the examination. Its use is, there-
fore, not recommended.
There is good evidence supporting the routine use of colour
or power Doppler for disease detection and activity assess-
ment during enteric US and hydosonography [74–79].
The routine use of contrast-enhanced US (CEUS) is
currently not recommended. However there are increas-
ing reports describing the utility of qualitative evalua-
tion of bowel wall vascularity patterns in CD using
CEUS [80, 81], as well as software defined quantitative
metrics from time-intensity curves such as time-to-peak,
peak enhancement and area under the curve [82–85].
Promising data for evaluation of CD activity against
an endoscopic reference have been reported [84, 86],
as well as utility in stricture characterisation [87], detec-
tion of postoperative recurrence [88], and treatment re-
sponse evaluation [89]. Apparent diagnostic benefit over
conventional US parameters is also described [85] .
However, there are no defined optimal thresholds for quan-
titative CEUS that differentiate active from inactive disease,
and there are differences in perfusion metrics between US
manufacturers. The precise role for CEUS in clinical practice
is likely to evolve as the evidence base grows.
If CEUS is performed the recommendations on dosage are
made on the most widely reported agent (sulphur
hexafluoride), although other agents are available. These are
based on manufacturer recommendations in the absence of
other evidence.
It is recommended that the practitioner specifically reports
if the extra enteric solid organs have been evaluated as part of
an US examination focused on the bowel. In some clinical
practices, it is expected the examination should evaluate the
whole abdomen and pelvis, including solid organs, although
targeted enteric US (e.g. for treatment follow-up) is also wide-
ly practiced.
Paediatric patients—specific considerations
Although in general, paediatric practice follows that of adults
[90, 91], there are important exceptions.
The use of CT is actively discouraged in the paediatric
population given the radiation exposure and should be re-
served for situations when neither MRI nor US can resolve
the clinical question.
Younger children do not tolerate prolonged fluid and food
restriction prior to examinations, and recommendations are
made according to the age of the patient, mainly based on
expert opinion.
Unlike adult practice, the use of spasmolytic prior to
MRE is considered optional in paediatric patients and
use is likely dependent on the age of the patient, with
older children more likely to tolerate spasmolytic injec-
tion. There are data supporting the benefits of glucagon
on image quality, at the expense of prolonged imaging
time and precipitation of nausea in just under half of
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paediatric patients [92, 93]. However, high diagnostic
accuracy can also be achieved without spasmolytic
[94]. The choice of spasmolytic, if used, mirrors adult
recommendations with due consideration of the age and
weight of the patient.
Recommendations for oral contrast volume and
spasmolytic/gadolinium dose are based on weight.
There are no specific recommendations as to the use
of hydroUS in the paediatric patient as practice is not
well developed. If oral contrast is given prior to US, it
would seem sensible to follow the recommendations for
MRE in the paediatric population.
Limitations
The modified Delphi process utilised in this document is
well established, although for the second face to face
meeting, not all committee members could attend, with
contributions made electronically. However a representa-
tive from each working group was present and all com-
mittee members subsequently scored their agreement with
each modified statement produced. Wherever possible,
recommendations were based on the detailed literature
review. However, in many areas there was no available
evidence, so recommendations were made based on the
combined expert opinion of the panel. This will be in-
fluenced by the experience and knowledge of the panel
members. To mitigate against potential bias, committee
members were selected based on publication record and
geographical location, and it was ensured that there was
experience in all modalities under consideration across
the consensus group. Discussions were moderated by
the committee chair who was independent of the work-
ing groups within the committee members. Finally, these
recommendations are relevant at the time of the consen-
sus process (2015/16). The literature in this field is rap-
idly expanding, and it is anticipated revised guidelines
will be required in the future.
In summary, a modified Delphi approach was suc-
cessfully utilised to produce set of guidelines to help
inform current best clinical practice in cross-sectional
small bowel and colonic imaging. For only a small
number of topics could an agreed consensus statement
not be produced by the committee. Whilst there is a
clearly a convergence in the literature as to basic tech-
niques, for many specific questions there is no clear
evidence base and statements were based on expert
opinion, with an emphasis on clinical practicability.
Based on the findings of the committee, particular
topics can be viewed as research priorities given their
potential impact on clinical practice. Examples include
the role of DWI and motility imaging as part of MRI
protocols , and more detai led guidance on i .v.
gadolinium contrast administration given the generally
young age of the imaged patient population, frequent
repeat imaging and increasing evidence of possible neu-
ronal retention of gadolinium for some contrast agent
classes [95]. The clinical utility of micro-bubble contrast
agents in small bowel US requires further clarity togeth-
er with the impact of further advances in dose reduction
techniques during CT examinations.
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